ABCL vs INCY
AbCellera Biologics Inc. vs Incyte — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
| Metric | ABCL | INCY |
|---|
| AI Score |
66
|
72
|
| Price |
$9.75
|
$121.08
|
| P/E Ratio |
-18.07×
|
14.89×
|
| ROE |
-15.1%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
92.6%
|
| Debt / Equity |
0.15×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
56.2
|
| Beta |
1.191
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus INCY.
INCY leads by 6 points.
INCY scores 72/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical